<bill session="117" type="s" number="2416" updated="2023-01-01T23:43:03Z">
  <state datetime="2021-07-21">REFERRED</state>
  <status>
    <introduced datetime="2021-07-21"/>
  </status>
  <introduced datetime="2021-07-21"/>
  <titles>
    <title type="official" as="introduced">A bill to amend title XVIII of the Social Security Act to provide for expedited coding and coverage of novel medical products, and for other purposes.</title>
    <title type="display">New Opportunities for Value that Extend Lives Act of 2021</title>
    <title type="short" as="introduced">New Opportunities for Value that Extend Lives Act of 2021</title>
    <title type="short" as="introduced">NOVEL Act of 2021</title>
  </titles>
  <sponsor bioguide_id="B001135"/>
  <cosponsors>
    <cosponsor bioguide_id="B001267" joined="2021-07-21"/>
    <cosponsor bioguide_id="C000174" joined="2021-07-21"/>
    <cosponsor bioguide_id="S001184" joined="2021-07-21"/>
  </cosponsors>
  <actions>
    <action datetime="2021-07-21">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2021-07-21" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Government information and archives"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Manufacturing"/>
    <term name="Medicare"/>
    <term name="Public participation and lobbying"/>
  </subjects>
  <amendments/>
  <summary date="2022-01-31T18:41:06Z" status="Introduced in Senate">New Opportunities for Value that Extend Lives Act of 2021 or the NOVEL Act of 2021 This bill establishes a process for expediting the assignment of Healthcare Common Procedure Coding System (HCPCS) codes to medical products that have been designated as a breakthrough product or regenerative advanced therapy by the Food and Drug Administration; it also establishes a process for determining coverage under Medicare of such breakthrough products that have been assigned HCPCS codes.</summary>
</bill>
